“It’s complicated” for CVS as the world’s tenth-highest-earning firm contemplates a breakup after several rocky quarters. With disappointing earnings, layoffs, and stagnant stock performance, CVS’s board is now exploring separation options. This move follows a trend of corporate dissections, like General Electric, Johnson & Johnson, and Liberty Media, aiming to eliminate the “conglomerate discount.”
- Originally a pharmacy and retailer, CVS expanded into a pharmacy benefit manager (PBM), health insurer, and healthcare clinic — but now retail is struggling, the FTC is suing PBMs, and rising treatment costs are squeezing insurers, bringing CVS’ market cap down to ~$78B.
- According to the WSJ, the breakup could separate its struggling retail stores and pharmacies from its more profitable insurance arm, Aetna — which CVS acquired seven years ago for $70B, nearly the same as the merged entity’s current market cap.
Breakup blues: Critics argue that splitting CVS could undo synergies and leave the retail division saddled with insurmountable debt. Supporters, however, believe leaner, more focused companies are the ideal remedy to boost performance and shareholder value. The challenge lies in deciding what to do with Caremark, CVS’s pharmacy benefit manager, which complements both sides. It’s clear there’s no easy fix for this messy relationship — but sometimes, a breakup is best for everyone.
